Popular terms

Immune Diseases topics
Immune Diseases
Autoimmune
Immune Disease
Autoimmune Disease
Autoimmune Diseases
Immune Disorder
Rheumatoid Arthritis
Antibodies
Antagonist
Nucleotide
Proliferative
Infectious
Infectious Disease
Infectious Diseases
Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Diseases patents



      

This page is updated frequently with new Immune Diseases-related patent applications.




Date/App# patent app List of recent Immune Diseases-related patents
02/04/16
20160033528 
 Methods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof patent thumbnailMethods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof
Provided herein is a method for selecting and expanding polypeptide epitopes against disease-specific antibodies present in blood across a wide variety of antibody-mediated infectious and autoimmune diseases. In particular, high-throughput selection methods are provided for selecting and expanding disease-relevant polypeptide epitopes against disease-specific antibodies present in a sample from a subject using polypeptide epitope libraries.
The Regents Of The University Of California


02/04/16
20160032018 
 Use of igg1 immunoglobulins and/or ligands of the cd32 receptor for treating inflammatory diseases and incidents via the mucosa patent thumbnailUse of igg1 immunoglobulins and/or ligands of the cd32 receptor for treating inflammatory diseases and incidents via the mucosa
The present invention concerns the use of immunoglobulins of igg1 type, and more generally of ligands of the cd32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.. .
Stallergenes Sa


02/04/16
20160031934 
 Dipeptide and tripeptide epoxy ketone protease inhibitors patent thumbnailDipeptide and tripeptide epoxy ketone protease inhibitors
Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of formula (x): and pharmaceutically acceptable salts and compositions including the same.
Onyx Therapeutics, Inc.


02/04/16
20160031891 
 Inhibitors of bruton's tyrosine kinase patent thumbnailInhibitors of bruton's tyrosine kinase
Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

02/04/16
20160030439 
 Methods for the treatment of autoimmune diseases patent thumbnailMethods for the treatment of autoimmune diseases
The present invention provides a method for inducing cd8+foxp3+ regulatory t cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates t-cell receptor (tcr) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject.
Ucl Business Plc


01/28/16
20160024508 
 Method for identifying biologically active oligonucleotides capable of modulating the immune system patent thumbnailMethod for identifying biologically active oligonucleotides capable of modulating the immune system
The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer..
Index Pharmaceuticals Ab


01/28/16
20160024220 
 Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis patent thumbnailPharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024219 
 Anti-cd52 antibodies patent thumbnailAnti-cd52 antibodies
Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation


01/28/16
20160024215 
 Llt-1 antibodies with new functional properties patent thumbnailLlt-1 antibodies with new functional properties
The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (llt1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which llt1- and cd161-expressing cells play a role in disease pathogenesis..
Centre National De La Recherche Scientifique


01/28/16
20160024183 
 Synthetic peptides for the treatment of autoimmune diseases patent thumbnailSynthetic peptides for the treatment of autoimmune diseases
The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


01/28/16
20160022788 

Compositions and methods for treating autoimmune diseases


The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more th2 promoting adjuvants. The compositions may optionally comprise one or more th2 promoting tlr2 ligands.
Albany Medical College


01/28/16
20160022767 

Protein particles comprising disulfide crosslinkers and uses


This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.
Emory University


01/28/16
20160022759 

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis


Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences


01/21/16
20160017024 

Fam150a, fam150b, and fam150 antagonists and uses thereof


Methods of identifying and using fam150a agents, fam150b agents, and fam150 antagonists are provided. Methods of identifying and using ltk agonists (including ltk agonist antibodies, fam150a agents, and fam150b agents) and fam150 antagonists are provided.
Five Prime Therapeutics, Inc.


01/21/16
20160016946 

Methods, compounds, and compositions for the treatment of angiotensin-related diseases


Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.. .
University Of Southern California


01/21/16
20160016904 

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof


The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (i) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
Arena Pharmaceuticals, Inc.


01/21/16
20160015751 

Method for enhancing a function of a t cell


Disclosed is a method for enhancing the function of a t cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (pd-l1) and/or programmed death-1 ligand 2 (pd-l2) in the t cell. Also disclosed is a function-enhanced t cell which is produced by the function enhancement method.
Takara Bio Inc.


01/21/16
20160015729 

Glycan-based drugs, therapies and biomarkers


The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed..

01/14/16
20160009687 

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 or bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


01/14/16
20160008608 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

01/14/16
20160008440 

Use of cd83 in combination therapies


The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of cd83. In some embodiments, cd83 is coadministered to a subject with at least one other immunosuppressive compound.
Argos Therapeutics, Inc.


01/14/16
20160008397 

Immunomodulation by controlling expression levels of micrornas in dendritic cells


Compositions and methods of modulating an immune response by controlling expression levels of micrornas in dendritic cells are disclosed. In particular, the invention relates to modified dendritic cells and methods of using such dendritic cells in cellular therapy for treating various immune conditions and diseases, including transplant rejection, inflammatory disorders, autoimmune diseases, allergies, infectious diseases, immunodeficiency, and cancer..
The Board Of Trustees Of The Leland Stanford Junior University


01/07/16
20160002243 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula (i) wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


01/07/16
20160002241 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Llc.


01/07/16
20160002225 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that inhibit bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

01/07/16
20160002206 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula i: (i) wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


01/07/16
20160002187 

Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


01/07/16
20160000877 

Compositions and methods for modulating gamma-c-cytokine activity


The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


01/07/16
20160000867 

Compositions and methods for modulating the immune system


A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Bioincept, Llc


01/07/16
20160000835 

Human uterine cervical stem cell population and uses thereof


The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment..
Fundacion Para La Investigacion Con Celulas Madre Uterinas


12/31/15
20150377879 

Peptoids that bind specific antigens


Combinatorial libraries were generated providing a vast number of diverse peptoid ligands. From these libraries, ligands were identified which specifically bind molecules associated with autoimmune diseases, such as antibodies specific to aquaporin-4 (aqp4), binding of which to aqp4 causes the autoimmune disease, neuoromyelitis optica.
The Scripps Research Institute


12/31/15
20150376294 

Anti-pad2 antibodies and treatment of autoimmune diseases


The present invention relates to anti-peptidylarginine deiminase 2 (pad2) antibodies and anti-pad2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (ra). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-pad2 antibody to a subject..
Rigshospitalet


12/31/15
20150376285 

Antibody molecule for human gm-csf receptor alpha


Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (gm-csfrα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g.
Zenyth Operations Pty. Ltd.


12/31/15
20150376174 

Azole benzene derivative


The present invention provides: a compound represented by formula (i) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.. .
Teijin Pharma Limited


12/31/15
20150376173 

Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent


The present invention relates to novel compounds of formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders..
Lg Life Sciences Ltd.


12/31/15
20150376166 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula (i): wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


12/31/15
20150374855 

Oral contrast medium for the diagnostic investigation of the gastrointestinal tract by means of mpi


The invention relates to a pharmaceutically acceptable colloidal suspension, which comprises a microcapsule, which is enclosed by a container (“double container”), wherein the microcapsules comprise magnetic particles in a colloidal solution. The invention further relates to the use of said pharmaceutically acceptable colloidal suspension as an oral contrast medium for the diagnostic investigation of the gastrointestinal tract and the use of the contrast medium to diagnose proliferative diseases, inflammatory and autoimmune diseases, infectious diseases and hormonal and hereditary diseases in the gastrointestinal tract..
Topass Gmbh


12/24/15
20150368611 

Induced regulatory t cell and use thereof


The present invention relates to a transduced t cell precursor prepared by introducing a gene construct comprising a polynucleotide encoding c/ebp (ccaat/enhancer binding protein) to a t cell precursor and overexpressing the c/ebp thereby, wherein the transduced t cell precursor is capable of differentiating into a regulatory t cell and an induced regulatory t cell differentiated therefrom. The transduced t cell precursor and the induced regulatory t cell may be useful for preventing and treating autoimmune diseases, inflammatory diseases and graft rejections caused by the malfunction of immune response..
Seoul National University R&db Foundation


12/24/15
20150368327 

Anti-semaphorin 3a antibody and treatment of alzheimer's disease and inflammatory immune diseases using same


The present invention mainly addresses the problem of providing an antibody against semaphorin 3a protein, said antibody enabling effective prevention and/or treatment of a disease, in which sema 3a protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. Or disseminated intravascular coagulation syndrome.
Chiome Bioscience Inc.


12/24/15
20150368261 

Conjugates and small molecules which interact with the cd16a receptor


The invention is related to medicine, in particular, to oncology and immunology. The novel compounds of the general formula 1 or 2, exhibiting affinity for cd16a receptor have been proposed.
Alla Chem, Llc


12/17/15
20150361039 

Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited


12/10/15
20150353534 

Thiazole derivatives as inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula i: wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


12/10/15
20150353514 

Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof


The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a triazamacrocyclic compound and at least one active molecule of a protein such as an antibody, in particular for the treatment of autoimmune diseases or for the treatment of cancer..
Biocellchallenge


12/10/15
20150352219 

Conjugate compounds


The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.. .
Callaghan Innovation Research Limited


12/10/15
20150352109 

Kinase inhibitor and treatment of related diseases


Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases..
Beijing Reciprocapharmaceuticals Co. Ltd.


11/26/15
20150337041 

Methods and compositions for treating autoimmune diseases or conditions


The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to nkg2d receptors present on the surface of cells underlying the disorders..
Fred Hutchinson Cancer Research Center


11/26/15
20150336966 

Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders


The present invention relates to certain substituted tricyclic acid derivatives of formula (i) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the s1p1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer..
Arena Pharmaceuticals, Inc.


11/19/15
20150330968 

Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions


The present invention relates to methods and assays for identifying agents capable of modulating gpr84 activity in cells, in particular agents that inhibit gpr84-agonist stimulated chemotaxis. Inhibition of gpr84-agonist stimulated chemotaxis is useful in the prevention and/or treatment of inflammatory conditions.
Galapagos Nv


11/19/15
20150329864 

Design of oligonucleotide analogs as therapeutic agents


It is believed that the compounds and compositions as described herein have therapeutic utility against a variety of diseases, including viral diseases, autoimmune diseases (such as, allergy, asthma, and inflammatory disorders) and cancer.. .

11/19/15
20150329637 

Depletion of il23r expressing cells in the treatment of various diseases


The present invention relates, for example, to depletion of il23r expressing cells in the treatment of disease and, in an embodiment thereof, to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in, for example, treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag


11/19/15
20150329541 

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
The Walter And Eliza Hall Institute Of Medical Research


11/05/15
20150315196 

Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases


Or a pharmaceutically acceptable salt or solvate thereof.. .

11/05/15
20150315191 

4-position substituted pyrazolopyrimidine derivative, and use thereof in drug preparation


The invention provides a new pyrazolopyrimidine derivative and a simple, efficient and low-cost preparation method thereof. The pyrazolopyrimidine derivative of the invention has good inhibitory activity for multiple kinases, has inhibitory action on multiple solid tumors, leukemia and autoimmune diseases, provides a new effective choice for preparation of kinase inhibitors, medicines for autoimmune diseases, angiogenesis inhibitors and antitumor drugs, and has good application prospect..

11/05/15
20150315189 

18f-labelled folates


The present invention is directed towards a new method of synthesis of 18f-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[f]fluoride, as well as 18f-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.. .
Merck & Cie


11/05/15
20150315128 

Bicyclic compounds


And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.



Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.697

5390

6 - 0 - 102